Nattawat Klomjit retweeted
Two Reviews @NEJM
Twenty years apart
Two great colleagues
Bob Kyle and Shaji Kumar
Nattawat Klomjit retweeted
In our new study in KI Reports we show how longitudinal monitoring of serum anti-podocin antibodies guided immunotherapy in a difficult case of steroid- and rituximab-resistant nephrotic syndrome sciencedirect.com/science/arā¦
Nattawat Klomjit retweeted
š§¬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025
authors.elsevier.com/a/1lSgWā¦
@AndrewMallett8 and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
Nattawat Klomjit retweeted
#Complement Activation in Secondary Thrombotic Microangiopathies (#TMA)
ā
Final version available in #OpenAccess in @NDTsocial
ā”ļø academic.oup.com/ndt/advanceā¦
š experts, colleagues and friends; the @ERAkidney Immunonephrology Working Group; and @AKronbichler for your leadership!
Nattawat Klomjit retweeted
The International Myeloma Working Group (IMWG) develops criteria for diagnosis, risk-strat, & response, provides current treatment guidelines, conducts collaborative research
Bookmark our website:
IMWG experts searchable by name and region IMWG.org @IMFmyeloma
Nattawat Klomjit retweeted
Sorry I accidentally deleted the original post while trying to answer some questions.
Iām still a novice with X š
Take home message: small ~3% of PLA2R negative MN cases by routine IF are PLA2R positive by LMD/MS.
kidney-international.org/artā¦
Nattawat Klomjit retweeted
Stunning interim results from the VISIONARY Phase 3 trial in IgA nephropathy!
Sibeprenlimab 400 mg led to a 51.2% placebo-adjusted reduction in 24h proteinuria (uPCR), with a -50.2% absolute reduction at 9 months! šµ
Placebo barely moved the needle: +2.1%.
š Early and sustained drop in spot uPCR confirmed.
šÆ A real game-changer on the horizon?
#ERA2025 #IgAN #Nephrology #Proteinuria #VISIONARYtrial #Sibeprenlimab #ClinicalTrials #GlomerularDisease #KidneyHealth #PrecisionMedicine
Nattawat Klomjit retweeted
More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.
š„ #CONFIDENCE in @NEJM
Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D
A new age of combination therapies has arrived in #CKM care #ERA25
nejm.org/doi/full/10.1056/NEā¦
Nattawat Klomjit retweeted
Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. @YiLinMDPhD @MayoMyeloma
#ASCO25
Comprehensive and covers CRS, neurotoxicity, infection prevention and more.
Link: msmart.org/mm-treatment-guidā¦
Nattawat Klomjit retweeted
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy
@LadanZand @basmeomeo @mvargas07 @SethiRenalPath @fervenzafernan1
kidney-international.org/artā¦
Nattawat Klomjit retweeted
Multiomic analysis of human kidney disease identifies a tractable inflammatory and pro-fibrotic tubular cell phenotype | ā¦@NatureCommsā© nature.com/articles/s41467-0ā¦
Nattawat Klomjit retweeted
The remarkable story of Velcade.
In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide
But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. @NEJM
Story in thread.
Nattawat Klomjit retweeted
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy - Kidney International @basmeomeo ā¦@fervenzafernan1ā© ā¦@SethiRenalPathā© kidney-international.org/artā¦
Nattawat Klomjit retweeted
Thank you @basmeomeo for coming all of the way to Boston to share your expertise!
Nattawat Klomjit retweeted
ANCA-negative pauci-immune GN is reported to occur in up to 30% of cases; in Europe, it has a prevalence of 1-5% of cases. Our multi-centre series reported the largest cohort of 132 cases and was just published in @KIReports
kireports.org/article/S2468-ā¦
Baseline char. are given!
Nattawat Klomjit retweeted
Anti-slit diaphragm antibodies in autoimmune podocytopathy:
ā¢Anti-nephrin ā frequent in kids
ā¢Anti-podocin ā in kids & adults
ā¢Anti-Kirrel1 ā more rare
ā¢Some patients have multiple autoantibodies.
journals.lww.com/jasn/citatiā¦
Nattawat Klomjit retweeted
Optimal Glucocorticoid Therapy in Lupus Nephritis
doi.org/10.1093/ndt/gfae294
Nattawat Klomjit retweeted
Amazing how Inebilizumab transforms IgG4RD into a controllable disease! Congratulations to my colleague Prof John Stone and team to this landmark trial!
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial @NEJM nejm.org/doi/full/10.1056/NEā¦
Nattawat Klomjit retweeted
#Tirzepatide SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 š
šSustained weight loss of 22.9% or an average 54lbs over 3 years
š½94% reduction in risk of progression to diabetes.
Number Needed to Treat = 9 š¤Æ
š«Improvement in metabolic parameters
This is the longest trial duration studying tirzepatide to date
Nattawat Klomjit retweeted
A super review of engineered T cells for cancer (CAR T and TILs)
jamanetwork.com/journals/jam⦠@JAMA_current @BrudnoN @MarcelaMaus @CSHinrichsMD







































